| Title | Adenoviral infection or deferoxamine? Two approaches to overexpress VEGF in beta-cell lines. | | Author(s) | Langlois A, Bietiger W, Sencier MC, Maillard E, Pinget M, Kessler L, Sigrist S | | Institution | Centre européen d'étude du Diabète, Strasbourg, France. | | Source | J Drug Target 2009 Jul; 17(6):415-22. | | Abstract | Rapid and adequate revascularization of transplanted islets is important for their survival and function during transplantation. Vascular endothelial growth factor (VEGF) could play a critical role with respect to islet revascularization. The aim of this study was to compare two strategies that are used to overexpress VEGF in beta-cells: (1) gene therapy through adenoviral infection and (2) a pharmacological approach using deferoxamine (DFO). beta-Cell lines from rat insulinoma (RINm5F) were either infected using an adenovirus encoding the gene of human VEGF 165 or incubated with DFO. One day after treatment, the viability of RINm5F cells was preserved with 10 mumol/L of DFO (103.95 +/- 5.66% toward control; n = 4). In addition, adenoviral infection maintained the viability of cells for all the concentrations used. In both treatments, overexpression of VEGF was in a comparable level. Finally, the ratio of Bax/Bcl-2 indicated that the apoptosis increased in infected beta-cells whereas treatment with DFO seems to be antiapoptotic. Our results suggest that the use of DFO could be a realistic approach to improve the vascularization of islets during transplantation. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19527112 |
|
